Areas of Focus
- 细胞生物学 - 血液肿瘤和造血干细胞的调控机制
- 病理学与病理生理学 - 血液肿瘤和造血干细胞的调控机制
Work Experience
- 2015-06~现在 - 中国科学院上海营养与健康研究所 - 研究员
- 2013-03~2015-05 - 美国迈阿密大学生物化学与分子生物学系 - 助理教授(tenure track)
- 2007-12~2013-03 - 美国纪念斯隆凯特琳癌症中心 - 博士后
- 2002-09~2007-07 - 中科院上海生命科学院健康科学研究所 - 生物化学与分子生物学博士
- 1998-09~2002-07 - 复旦大学生命科学院 - 生物学士
Academic Background & Achievements
- 2002-09--2007-07 生物化学与分子生物学博士: 中科院上海生命科学院健康科学研究所
- 1998-09--2002-07 生物学士: 复旦大学生命科学院
Publications
- SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis, 未提及, 2024
- S100a9 deficiency accelerates MDS associated tumor escape via PD-1/PD-L1 overexpression, 未提及, 2023
- Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B cell lymphoma, 未提及, 2023
- The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment. Blood, 未提及, 2023
- ROBO1 deficiency impairs HSPCs homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS, 未提及, 2023
- Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia, 未提及, 2022
- Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B cell lymphoma, 未提及, 2021
- SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS, 未提及, 2020
- Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis, 未提及, 2019
- Destabilization of AETFC through C/EBP-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation, 未提及, 2019
- Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner, 未提及, 2017
- Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin, 未提及, 2016
- Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5): 640-650, 未提及, 2016
- PARP inhibitors: a treatment option for AML?, 未提及, 2015
- The role of histone acetyltransferase in normal and malignant hematopoiesis, 未提及, 2015
- Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia, 未提及, 2008
- Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-κB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner, 未提及, 2007
- Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo, 未提及, 2007
- Histone deacetylase inhibitor promotes rituximab-induced apoptosis in non-Hodgkin’s B-lymphoma cells by NF-κB-mediated Bcl-2/Bcl-XL downregulation and c-Myc degradation, 未提及, 2007
- The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation, 未提及
- Post-translational modifications of Runx1 regulate its activity in the cell, 未提及